Is There a Role for Interleukin-2 Gene Transfer in the Management of Acute Leukemia?

  • Robert Foa
  • Alessandro Cignetti
  • Anna Gillio Tos
  • Anna Carbone
  • Paola Francia do Celle
  • Anna Guarini
Conference paper
Part of the Haematology and Blood Transfusion / Hämatologie und Bluttransfusion book series (HAEMATOLOGY, volume 37)


The limitations encountered with the administration of high dose exogenous interleukin-2 (IL-2) have triggered the search for alternative immunotherapeutic approaches or delivery modalities. Studies carried out in experimental tumor models suggest that the tumor-genic potential can be reversed following transduction of different cytokine genes into the DNA of the neoplastic cells. Transfer of the IL-2 gene has also been associated with the generation of anti-tumor specificity and anti-tumor memory. These findings have led to the activation of the first clinical vaccination protocols with human tumor cells engineered to release IL-2 in patients suffering from different tumors. Here, we shall report on the feasability of inserting the IL-2 gene into human acute leukemia cells and the possibility of using this approach for the management of patients with acute leukemia.


Renal Cell Carcinoma Acute Myeloid Leukemia Acute Leukemia Autologous Bone Marrow Transplantation Acute Leukemia Patient 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Rosenberg SA, Lotze MT, Muul LM et al (1987): A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. New England Journal of Medicine 316: 889–897PubMedCrossRefGoogle Scholar
  2. 2.
    West WH, Tauer KW, Yannelli JR et al (1987): Constant-infusion recombinant intelreukin-2 in adoptive immunotherapy of advanced cancer. New England Journal of Medicine 316: 898–905PubMedCrossRefGoogle Scholar
  3. 3.
    Rosenberg SA, Lotze MT, Anyg JC et al. (1989): Experience with the use of high-dose interleukin-2 in the treatment of 652 cancer patients. Annals Surgery 210: 474–484CrossRefGoogle Scholar
  4. 4.
    Foa R (1994):Does Interleukin-2 have a role in the management of acute leukemia? Journal of Clinical Oncology 11: 1817–1825Google Scholar
  5. 5.
    Oshimi K, Oshimi Y, Akutsu M et al (1986): Cytotoxicity of interleukin 2 activated lymphocytes for leukemia and lymphoma cells. Blood 68: 938–948PubMedGoogle Scholar
  6. 6.
    Lotzova E, Savary CA, Herberman RB (1987): Inhibition of clonogenic growth of fresh leukemia cells by unstimulated and IL-2 stimulated NK cells of normal donors. Leukemia Research 11: 1059–1066PubMedCrossRefGoogle Scholar
  7. 7.
    Fierro MT, Xin-Sheng L, Lusso P et al. (1988): In vitro and in vivo susceptibility of human leukemic cells to lymphokine activated killer activity. Leukemia 2: 50–54PubMedGoogle Scholar
  8. 8.
    Foa R, Caretto P, Fierro MT et al. (1990): Interleukin 2 does not promote the in vitro and in vivo proliferation and growth of human acute leukaemia cells of myeloid and lymphoid origin. British Journal of Haematology 75: 34–40PubMedCrossRefGoogle Scholar
  9. 9.
    Foa R, Caretto P, Tosti S et al. (1990): Induction and persistence of complete remission in a resistant acute myeloid leukemia patient following treatment with recombinant interleukin 2. Leukemia and Lymphoma 1: 113–177CrossRefGoogle Scholar
  10. 10.
    Meloni G, Foa R, Tosti S et al. (1990): IL-2 in the treatment of chronic myeloid leukemia after lymphoid blast crisis: a pilot study. Haematologica 75: 502–505PubMedGoogle Scholar
  11. 11.
    Foa R, Meloni G, Tosti S et al (1991a): Treatment of acute myeloid leukaemia patients with recombinant interleukin 2: a pilot study. British Journal of Haematology 77: 491–496CrossRefGoogle Scholar
  12. 12.
    Maraninchi D, Blaise D; Viens P et al. (1991): High-dose recombinant interleukin-2 and acute myeloid leukemias in relapse. Blood 78: 2182–2187PubMedGoogle Scholar
  13. 13.
    Lim SH, Newland AC, Kelsey S et al (1992): Continuous intravenous infusion of high-dose recombinant interleukin-2 for acute myeloid leukaemia — a phase II study. Cancer Immunology and Immunotherapy 34: 337–342PubMedCrossRefGoogle Scholar
  14. 14.
    Meloni G, Foa R, Vignetti M et al (1994): Interleukin 2 may induce prolonged remissions in advanced acute myelogenous leukaemia. Blood, in pressGoogle Scholar
  15. 15.
    Blaise D, Olive D; Stoppa AM et al. (1990) Hematologic and immunologic effects of the systemic administration of recombinant interleukin-2 after autologous bone marrow transplantation for hematologic malignancies. Blood 76: 1092–1097PubMedGoogle Scholar
  16. 16.
    Higuchi CM, Thompson JA, Petersen FB, Bruckner CD, Fefer A (1991): Toxicity and immunomodulatory effects of interleukin-2 after autlogous bone marrow transplantation for hematologic malignancies. Blood 77: 2561–2568PubMedGoogle Scholar
  17. 17.
    Meloni G, Foa R, Tosti S et al (1992): Autologous bone marrow transplantation followed by interleukin-2 in children with advanced leukemia: a pilot study. Leukemia 6: 780–785PubMedGoogle Scholar
  18. 18.
    Soiffer RJ, Murray C, Cochran K et al (1982): Clinical and immunologic effects of prolonged infusion of low-dose recombinant interleukin-2 after autologous and T-cell depleted allogeneic bone marrow transplanation. Blood 79: 517–526Google Scholar
  19. 19.
    Benyunes MC, Massumoto C, Higuchi CM et al. (1993): Interleukin-2 with or without lymphokine-activated killer cells as consolidative immunotherapy after autologous bone marrow transplantation for acute myelogenous leukemia. Bone Marrow Transplantation 12: 159–163PubMedGoogle Scholar
  20. 20.
    Sondel PM, Kohler PC, Hank JA et al. (1988): Clinical and immunological effect of recombinant interleukin 2 given by repetitive cycles to patients with cancer. Cancer Research 48:: 2561–2567PubMedGoogle Scholar
  21. 21.
    Favrot MC, Combaret V, Negrier S et al. (1990): Functional and immunophenotypic modifications induced by interleukin-2 did not predict response to therapy in patients with renal cell carcinoma. Journal of Biological Response Modifiers 9: 167–177PubMedGoogle Scholar
  22. 22.
    Gottlieb DJ, Prentice HG, Heslop HE et al. (1989): Effects of recombinant interleukin-2 administration on cytotoxic function following high-dose chemo-radiotherapy for hematological malignancy. Blood 74: 2335–2342PubMedGoogle Scholar
  23. 23.
    Foa R, Guarini A; Gillio Tos A et al. (1991b): Peripheral blood and bone marrow immunophenotypic and functional modifications induced in acute leukemia patients treated with Interleukin 2: Evidence of in vivo lymphokine activated killer cell generation. Cancer Research 51: 964–968Google Scholar
  24. 24.
    Heslop HE, Gottlieb DJ, Bianchi ACM et al. (1989): In vivo induction of gamma interferon and tumor necrosis factor by interleukin-2 infusion following intensive chemotherapy or autologous marrow transplantation. Blood 74: 1374–1380PubMedGoogle Scholar
  25. 25.
    Lissoni B, Barni S, Tancini G et al. (1994): A randomised study with subcutaneous low-dose interleukin-2 alone versus interleukin-2 plus the pineal neurohormone melatonin in advanced solid neoplasms other than renal cancer and melanoma. British Journal of Cancer 69: 196–199PubMedCrossRefGoogle Scholar
  26. 26.
    Foa R, Guarini A, Cignetti A et al. (1994): Cytokine gene therapy: a new strategy for the management of cancer patients. Natural Immunity 13: 65–75PubMedGoogle Scholar
  27. 27.
    Colombo MP, Forni G (1994): Cytokine gene transfer inhibition and tentative tumor therapy: where are we now? Immunology Today 15: 48–51PubMedCrossRefGoogle Scholar
  28. 28.
    Forni G, Parmiani G, Guarini A, Foa R (1994): Gene transfer in tumor therapy. Annals of Oncology, in pressGoogle Scholar
  29. 29.
    Fearon ER, Pardoll DM, Itaya T et al. (1990): Interleukin-2 production by tumor cells bypasses T helper function on the generation of an antitumor response. Cell 60: 3997–403CrossRefGoogle Scholar
  30. 30.
    Gansbacher B, Zier K, Daniels B et al. (1990): Interleukin-2 gene tranfer into tumor cells abrogates tumorigenicity and induces protective immunity. Journal of Experimental Medicine 172: 1217–1224PubMedCrossRefGoogle Scholar
  31. 31.
    Ley V, Langlade-Demoyen P, Kourilsky P, Larsson-Sciard L (1991): Interleukin 2-dependent activation of tumor-specific cytotoxic T lymphocytes in vivo. European Journal of Immunology 21: 851–854PubMedCrossRefGoogle Scholar
  32. 32.
    Gansbacher B, Zier K, Cronin K et al. (1992): Retroviral gene tranfer induced constitutive expression of interleukin-2 or interferon-γ in irradiated human melanoma cells. Blood 80: 2817–2825PubMedGoogle Scholar
  33. 33.
    Gastl G, Finstad CL, Guyrini A et al. (1992): Retroviral vector-mediated lymphokine gene transfer into human cancer cells. Cancer Research 52: 6229–6236PubMedGoogle Scholar
  34. 34.
    Foa R, Guarini A, Gansbacher B (1992): IL2 treatment for cancer: from biology to gene therapy. British Journal of Cancer 66: 992–998PubMedCrossRefGoogle Scholar
  35. 35.
    Belldegrun A, Tso C-L, Sakata T et al. (1993): Human renal carcinoma line tranfected with interleukin-2 and/or interferon α gene(s): implications for live cancer vaccines. Journal of the National Cancer Institute 85: 207–216PubMedCrossRefGoogle Scholar
  36. 36.
    Guarini A; Gansbacher B, Cronin B et al. (1994): Specific T lymphocyte reactivity to IL-2 gene transduced human melanoma cells. In: Forni G, Foa R, Santoni A, Frati L (eds): Cytokine Induced Tumor Immunogenicity, London, UK: Academic Press, 403–413Google Scholar
  37. 37.
    Cignetti A, Guarini A; Carbone A et al. (1994): Tranduction of the IL2 gene into human acute leukemia cells: induction of tumor rejection without modifying cell proliferation and IL2 receptor expression. Journal of the National Cancer Insitute 86: 785–791CrossRefGoogle Scholar
  38. 38.
    Foa R, Fierro MT, Cesano A et al. (1991c): Defensive lymphokine-activated killer cell generation and activity in acute leukemia patients with active disease. Blood 78: 1041–1046Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1996

Authors and Affiliations

  • Robert Foa
    • 1
    • 2
  • Alessandro Cignetti
    • 1
  • Anna Gillio Tos
    • 1
  • Anna Carbone
    • 1
  • Paola Francia do Celle
    • 1
  • Anna Guarini
    • 1
  1. 1.Dipartimento di Scienze Biomediche e Oncologia UmanaSezione ClinicaItaly
  2. 2.Centro NR Immunogenetica e Oncologia SperimentaleUniversity of TurinTurinItaly

Personalised recommendations